Effect Observation Study of COX-2 Inhibitor to Treat Primary Hypertrophic Osteoarthropathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-12-31

Study Completion Date

2016-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether COX-2 inhibitor is effective in the treatment of primary hypertrophic osteoarthropathy

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Postoperative Intravenous Parecoxib Sodium Followed by Oral Celecoxib in Osteoarthritis Patients

NCT02198924

Pain Inflammation

COMPLETED PHASE4

Effect Of Meloxicam Versus Placebo In Mainland Chinese Patients With Osteoarthritis Of The Knee

NCT01430559

Osteoarthritis of the Knee

COMPLETED NA

Evaluation of GW406381 in Treating Adults With Osteoarthritis Of The Knee

NCT00120900

Osteoarthritis, Knee

COMPLETED PHASE3

Efficacy Management and Adherence Evaluation of Diclofenac in the Treatment of Knee Osteoarthritis Pain

NCT03806205

To Investigate the Effect of Diclofenac on Pain Control of Knee Osteoarthritis and the Relationship Between Pain Relief and Medicine Adherence

UNKNOWN NA

Study of FX005 for the Treatment of Pain in Patients With Osteoarthritis of the Knee

NCT01291914

Osteoarthritis, Knee

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with primary hypertrophic osteoarthropathy(PHO) were diagnosed based on clinical manifestations and symptoms. PHO patients were treated with COX-2 inhibitor after signing informed consent. The extend of alleviation, the change of the markers on prostaglandin E metabolic pathway and the adverse event on different time points were recorded to identify the efficacy and safety.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Hypertrophic Osteoarthropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

COX-2 Inhibitor

Patients who take COX-2 inhibitor

Group Type EXPERIMENTAL

COX-2 inhibitor

Intervention Type DRUG

oral COX-2 inhibitor intake 60mg qd

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

COX-2 inhibitor

oral COX-2 inhibitor intake 60mg qd

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

EtoriCoxib

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* diagnosed with primary hypertrophic osteoarthropathy clinically
* over 16 years old
* no other medication intake
* informed consent signed

Exclusion Criteria

* below 16 years old
* active gastric ulcer
* inflammatory bowel disease
* New York Heart Association classification（NYHA） II to IV
* liver or renal failure
* allergic to nonsteroid anti-inflammatory drugs
* not willing to participate

Minimum Eligible Age

16 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Weibo Xia, MD

Role: STUDY_CHAIR

Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences